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Abstract
Thrombospondin type 1 repeats (TSRs), small adhesive protein domains with a wide range of 
functions, are usually modified with O-linked fucose, which may be extended to O-fucose-β1,3-
glucose. Collision-induced dissociation (CID) spectra of O-fucosylated peptides cannot be 
sequenced by standard tandem mass spectrometry (MS/MS) sequence database search engines 
because O-linked glycans are highly labile in the gas phase and are effectively absent from the 
CID peptide fragment spectra, resulting in a large mass error. Electron transfer dissociation (ETD) 
preserves O-linked glycans on peptide fragments, but only a subset of tryptic peptides with low 
m/z can be reliably sequenced from ETD spectra compared to CID. Accordingly, studies to date 
that have used MS to identify O-fucosylated TSRs have required manual interpretation of CID 
mass spectra even when ETD was also employed. In order to facilitate high-throughput, automatic 
identification of O-fucosylated peptides from CID spectra, we re-engineered the MS/MS sequence 
database search engine Comet and the MS data analysis suite Trans-Proteomic Pipeline to enable 
automated sequencing of peptides exhibiting the neutral losses characteristic of labile O-linked 
glycans. We used our approach to re-analyze published proteomics data from Plasmodium 
parasites and identified multiple glycoforms of TSR-containing proteins.
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INTRODUCTION
Thrombospondin type 1 repeats (TSRs) are small (~60 amino acid residues) adhesive protein 
domains with a wide range of functions 1. TSRs are often modified with two unique glycans, 
O-linked fucose (O-Fuc) and C-linked mannose (C-Man). The motif CX2–3(S/T)CX2G is 
recognized by the O-fucosyltransferase POFUT2 2 and can be modified with O-Fuc at the 
serine/threonine (Ser/Thr or S/T) residue 3. This fucose can be further extended to a fucose-
β1,3-glucose disaccharide (O-Fuc-Glc) by the β1,3-glucosyltransferase B3GLCT 4–5. TSRs 
also often contain WXXW and WXXC motifs that can be modified with a C-linked mannose 
(C-Man) at the tryptophan (Trp or W) residues 6–7. In C. elegans, where the first C-
mannosyltransferase was discovered 8, the enzyme Dpy19 only C-mannosylates the first Trp 
of the WXXW motif. However, it has recently been shown that humans possess multiple 
homologs of Dpy19, and that Dpy19L1 preferentially modifies the first Trp of WXXW 
while Dpy19L3 preferentially modifies the Trp of WXXC 9. In TSRs, all of these motifs 
often appear in tandem as [WXX]1–3CXX(S/T)CXXG, and this short sequence may be 
modified with multiple combinations of C-Man, O-Fuc, and O-Fuc-Glc within the same 
organism, and even on the same protein 3. The role of these TSR glycosylations is not fully 
characterized, and appears to vary by protein. In experiments where POFUT2 or Dpy19 have 
been deleted, certain TSR-containing proteins exhibit stability and trafficking defects, while 
other TSR-containing proteins show no discernable defect from loss of glycosylation 9–10.
Given the heterogeneity of site occupancy and function observed to date for glycosylated 
TSRs, it is desirable to be able to detect and quantify TSR glycosylation in vivo. Mass 
spectrometry (MS) is typically the method of choice for high-throughput detection of protein 
post-translational modifications (PTMs) because a moiety covalently bound to a peptide can 
be directly detected as a mass shift, and the residue to which said modification is attached 
can usually be directly inferred from the MS2 fragment spectra. However, detection of O-
fucosylation of TSRs by MS is hindered by the fact that these O-linked glycans are highly 
labile in the gas phase 3 and are present at very low abundance or absent from the collision 
induced dissociation (CID) and higher-energy collision (HCD) MS2 peptide fragment 
spectra that are typically used to sequence peptides in shotgun proteomics experiments. 
When the majority of fragment ions lack the glycan due to neutral loss, typical MS/MS 
sequence database search programs are incapable of identifying the peptide at all because of 
the large discrepancy between the precursor parent mass (with the glycan intact) and the 
masses of the deglycosylated fragments in the MS2 spectrum. It has been demonstrated that 
a subset of peptides modified with O-Fuc may be sequenced by MS/MS sequence database 
search engines if they were fragmented with electron transfer dissociation (ETD), which 
leaves the O-linked glycan intact 11–12. However, ETD tends to only produce quality 
fragment spectra at lower m/z, and many of the tryptic peptides that are readily sequenced 
from CID and HCD spectra cannot be sequenced using ETD 13. For these reasons, the most 
common approach to identifying O-fucosylation of TSRs has been to manually interpret 
CID and HCD mass spectra of peptides bearing the predicted glycosylation motifs, 
elucidating the sequence of the peptide by the unmodified fragment ions, and inferring the 
identity of the O-linked glycan by the mass of the neutral loss 3, 14.
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In order to facilitate automatic identification of O-Fuc and O-Fuc-Glc from typical CID and 
HCD shotgun proteomics experiments, we re-engineered several open-source software tools 
for proteomics data analysis in order to enable automated sequencing and annotation of 
peptides exhibiting the neutral losses characteristic of gas-phase-labile PTMs. To 
demonstrate the utility of our approach, we re-analyzed published proteomics data that had 
previously been manually interpreted to identify O-fucosylation of TSRs in the Plasmodium 
parasites P. falciparum and P. vivax. Our method validated these results with dozens of 
automatically identified and annotated corroborating spectra. We were also able to use our 
approach to identify the first evidence for TSR glycosylation in P. yoelii.
EXPERIMENTAL PROCEDURES
Sample preparation
A segment of P. falciparum circumsporozoite protein (CSP; PF3D7_0304600) bearing the 
TSR domain was expressed in HEK293 cells and purified as described elsewhere 15. One 
hundred µg of purified protein was resuspended in 100 µL of 50 mM ammonium bicarbonate 
(ABC) and 5 mM tris(2-carboxyethyl)phosphine (TCEP; (ThermoFisher Bond-Breaker 
Neutral pH solution) and incubated 15 min at 50 °C, then added to a Microcon YM-3 3 kDa 
molecular weight cut-off filter (Amicon Bioseparations) that had been washed with ABC. 
After reducing the buffer volume by centrifugation, 100 µL of 10 mM iodoacetamide (IAM) 
in 50 mM ABC was added to the filter and incubated 20 min at room temperature (RT) in 
darkness. The IAM was removed by centrifugation, the filter was washed once with 100 µL 
of 50 mM ABC, and 2 µg of trypsin (Promega, sequencing grade) in 50 µL of 50 mM ABC 
was added to the filter, mixed by vortexing 1 min at 600 RPM in a thermomixer, and 
incubated overnight at 37 °C. The digested peptides were collected by centrifugation, dried 
in vacuum concentrator, and reconstituted in 50 % (v/v) methanol/0.1 % (v/v) formic acid 
(FA) to a nominal peptide concentration of 1 pmol/µL.
Recombinant P. falciparum thrombospondin-related anonymous protein (TRAP; 
PF3D7_1335900) was expressed in HEK293 cells and purified as described elsewhere 16. 
Six µg of PfTRAP was digested with trypsin using an S-Trap Micro (Protifi) following the 
manufacturer’s instruction. Briefly, to a 6 µL aliquot of a 1 µg/µL solution of purified protein 
in HEPES/NaCl buffer, 0.6 µL of 0.5 M TCEP was added (final concentration 45 mm) and 
incubated 5 min at 95 °C. The solution was cooled and 0.6 µL of 1 M IAM was added and 
incubated 20 min at RT in darkness. Lysis buffer (5 % (w/v) sodium dodecyl sulfate (SDS) 
in 50 mM ABC) was added to achieve a final volume of 25 µL, followed by 2.5 µL of 12 % 
(v/v) phosphoric acid, then 165 µL of S-Trap buffer (100 mM ABC in 90 % (v/v) methanol). 
The colloidal protein precipitate that formed was collected on the S-Trap by centrifugation 
and washed three times with S-Trap buffer, after which 2 µg of trypsin in 20 µL of 50 mM 
ABC was placed on the trap. The trap was incubated 1 h at 47 °C and the peptides were 
collected by centrifugation, followed by three additional 40 µL washes of 50 mM ABC, 
0.2 % (v/v) FA, and 50 % (v/v) acetonitrile (ACN). All elution steps were combined, dried 
in a vacuum concentrator, and reconstituted in 5 % (v/v) ACN/1 % (v/v) trifluoroacetic acid 
(TFA) to a nominal peptide concentration of 0.2 µg/µL.
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Mass spectrometry
Mass spectrometry (MS) was performed on an LTQ-Velos Pro Orbitrap Elite 
(ThermoFisher). The PfCSP tryptic digest was infused directly at 500 nL/min through an 
empty Picofrit column (New Objective) with a 75 µm internal diameter (ID) and a 15 µm ID 
fritted tip. Mass spectra, including collision-induced dissociation (CID) and higher-energy 
dissociation (HCD) MSn were collected in the Orbitrap with a nominal resolution of 240,000 
at 400 m/z. Spectra were acquired through the direct acquisition function in the instrument 
tune window. Ten spectra were collected for each combination of normalized collision 
energy (CE) and MSn and signal-averaged in XCalibur to produce the spectra presented 
here. The PfTRAP tryptic digest was analyzed by nanoflow liquid chromatography (LC)-MS 
using an Agilent 1100 with electronically controlled split-flow coupled to the MS. Injections 
of nominally 0.16 or 0.2 µg of peptides were loaded onto a 150 µm ID fused silica trap 
column made in-house with a 10 mm bed of C18 (Dr. Maisch ReproSil Pur C18 AQ, 120 Å, 
3 µm) and washed with LC load buffer (2% (v/v) ACN/0.2 % (v/v) trifluoroacetic acid 
(TFA)) prior to separation on a column packed in-house with a 20 cm bed of the same 
stationary phase in a Picofrit column with a 75 µm ID and a 10 µm ID fritted tip. Mobile 
phase A was 0.1 % (v/v) FA in H2O and mobile phase B was 0.1 % (v/v) (FA) in ACN. The 
separation gradient was as follows, all at 300 nL/min: 5 % B to 35 % B in 60 min, 35 % B to 
80 % B in 10 min, 5 min at 80 % B, 80 % B to 5 % B in 1 min, and 29 min at 5 % B to re-
equilibrate the column. For the collision energy (CE) scanning experiment, MS1 scans were 
collected in the Orbitrap from 400 – 1500 m/z at a resolution of 30,000. A data-dependent 
acquisition (DDA) method was employed to select the eight most abundant precursors for 
CID with a normalized CE of 35 %. CID spectra were collected in the Orbitrap at a 
resolution of 15,000. Monoisotopic precursor selection was enabled. Singly charged 
precursors and those with unassigned charge states were excluded from selection. An 
inclusion list was employed to preferentially select 1248.01 m/z and 1329.03 m/z at CEs of 
0, 5, 10, 15, 20, 25, 30, and 35 %. Dynamic exclusion was not enabled. For the experiment 
targeting the multiple glycoforms of the glycosite-containing peptide, the MS method was 
modified such that the MS1 scans were collected over 1000 – 1500 m/z and only doubly 
charged precursors were selected for fragmentation. The inclusion list is provided in Table 
S1.
Software
The tandem mass spectrometry sequence database search engine Comet 17 was re-
engineered to support the analysis of precursor mass offsets by the implementation of the 
“mass_offsets” parameter. Within the Comet code, this functionality is a simple extension to 
the precursor mass check function where each user defined mass offset value is subtracted 
from the experimental precursor mass such that peptides that are smaller than the 
experimental precursor mass by the mass offset value can still be matched to the spectrum. 
Multiple mass offsets can be specified within a single search. This function was first 
implemented in Comet version 2015.02 rev.0.
The peptide spectrum matches (PSMs) produced by Comet were analyzed using the Trans-
Proteomics Pipeline (TPP) version 5.1.0 Syzygy18 . In this version, the TPP spectrum level 
validation tool PeptideProphet was modified to accommodate PSMs obtained with the 
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mass_offsets parameter enabled in Comet. Specifically, PeptideProphet has a mass 
difference model that accounts for mass differences between the measured mass of the 
precursor ion and the theoretical mass of the matched peptide. This model aims to increase 
the probability of PSMs that have a small mass difference between the measured and 
theoretical masses and decrease the probability of PSMs that have a large mass difference, 
with the actual parameters of the model learned from the dataset using the EM algorithm. 
Considering the mass_offsets parameter in Comet, where the PSMs can now have a possible 
number of large mass offsets and still be correct, this model had to be adjusted. Given that 
the mass error of PSMs coming from searched peptides at a non-zero mass offset are 
expected to be off by the mass of the lost modification for every PSM and for every possible 
mass offset, the mass difference model in PeptideProphet finds the correct mass difference 
by considering the mass differences between the measured precursor mass and the matched 
peptide mass with the appropriate mass offset to correct for the neutral loss of the labile 
modification. After considering all possible mass offsets, the mass difference that is closest 
to zero is used as the corrected mass difference for consideration in the mass difference 
model.
Additionally, the spectrum viewing tool Lorikeet (http://uwpr.github.io/Lorikeet/), which is 
incorporated into the TPP, was updated to automatically annotate features specific to C-
mannosylated peptides. Upon recognizing modification of Trp residues with a mass of 
162.05 (hexose), the viewer now provides the option of annotating neutral loss of 120.04 
(from cross-ring cleavage of C-Man) from the precursor and putatively hexosylated 
fragments.
Peak list generation
The MS data and associated database and analysis files generated for this work are available 
at www.peptidatlas.org 19 using the identifier PASS01201. The MS data from previously 
reported analyses of salivary gland sporozoites 20–22 were obtained from PeptideAtlas using 
the identifiers PASS00095 and PASS00729 (P. falciparum salivary gland sporozoites), 
PASS00098 (P. yoelii salivary gland sporozoites), and PASS00976 (P. vivax salivary gland 
sporozoites). Mass spectrometer output files were converted to mzML format using 
msConvert version 3.0.6002 from the ProteoWizard toolkit 23 and searched with Comet 
version 2017.01 rev.1 17. The precursor mass tolerance was set to ±10 ppm. For the 
recombinant PfTRAP LC/MS data, for which the MS2 were collected at high resolution in 
the Orbitrap, the fragment ions bins were set to a tolerance of 0.02 m/z, the monoisotopic 
mass offset was 0.0, and the theoretical fragment ions setting was set at 0 (“use flanking 
peaks”). For the sporozoite global proteome data, for which the MS2 were collected at low 
resolution in the LTQ, the bin tolerance was set to 1.0005 m/z, the monoisotopic mass offset 
was set to 0.4 m/z, and the theoretical fragment ions setting was 1 (“M peak only”). Semi-
tryptic peptides and up to 2 missed cleavages were allowed. The search parameters included 
a static modification of +57.021464 Da at Cys for formation of S-carboxamidomethyl-Cys 
by IAM and potential modifications of +15.994915 Da at Met and Trp for oxidation, 
+31.989829 Da at Trp for dioxidation, and +162.052824 Da at Trp for C-mannosylation. 
The mass_offset parameter was set to allow mass offsets of 0, +146.057909, and 
+308.1107321 Da for no neutral loss and neutral loss of deoxyhexose or 
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hexosyldeoxyhexose, respectively. The recombinant PfTRAP spectra were searched against 
a database comprising P. falciparum TRAP (PF3D7_1335900) and the common Repository 
of Adventitious Proteins (v.2012.01.01, The Global Proteome Machine, www.thegpm.org/
cRAP, 116 entries). The sporozoite data were searched against P. falciparum 3D7 24 
(PlasmoDB v.35, www.plasmodb.org 25, 5548 entries), P. yoelii yoelii 17X 26 (PlasmoDB v.
35, 6092 entries), or P. vivax P01 27 (PlasmoDB v.31) appended with sequence 
polymorphisms observed in other field isolates 22 (6670 entries), as appropriate for the 
sample. Each of these Plasmodium databases was appended with the mosquito protein 
database Anopheles stephensi Indian AsteI2.3 28 (VectorBase, www.vectorbase.org 29, 
11789 entries), and the cRAP proteins. For each database, decoy proteins with the residues 
between tryptic residues randomly shuffled were generated using a tool included in the TPP 
and interleaved among the target entries. The MS2 spectra were analyzed using the TPP 
version 5.1.0 Syzygy. PSMs were assigned scores in PeptideProphet 30 using the following 
options: nonparametric model (NONPARAM), use Expect value as the only contributor to 
the f-score (EXPECTSCORE), accurate mass binning of high-accuracy precursor mass 
(ACCMASS PPM), report results with minimum probability of zero (ZERO), identify decoy 
entries in the database and use decoys to build models (DECOY=DECOY). For the 
recombinant PfTRAP data, only very high-quality PSMs were counted (those identified with 
a PeptideProphet probability of 1.0 and an Expect score less than 10−5). For the re-analysis 
of sporozoite proteome datasets, the DECOYPROBS flag was used to assign possible non-
zero probabilities to decoy entries, enabling determination of the decoy-estimated false 
discovery rate (FDR) among peptides identified with mass shifts. Only PSMs identified with 
a PeptideProphet probability corresponding to a model-estimated FDR less than 1.0 % were 
taken for further analysis.
RESULTS AND DISCUSSION
Behavior of O-fucose and C-mannose in collision-induced dissociation.
The TSR-containing proteins circumsporozoite protein (CSP) and thrombospondin-related 
anonymous protein (TRAP) are major surface proteins of salivary gland sporozoites, the 
form of the Plasmodium parasite that is transmitted from the mosquito vector to the 
vertebrate host. Expressing CSP and TRAP in HEK293 cells has been shown to modify the 
TSRs of these proteins with C-Man and O-Fuc-Glc 15, 31–32. We analyzed recombinant P. 
falciparum CSP and TRAP by tandem mass spectrometry (MS/MS) and nano-flow liquid 
chromatography (nanoLC)-MS/MS in order to characterize the behavior of O-Fuc and C-
Man in CID. The recombinant PfCSP was digested with trypsin and infused for direct 
analysis by nanospray ionization (NSI)-MS/MS. Based on signal intensity of the parent ions, 
~92% of glycosite-bearing peptide was modified with a mass equal to hexose plus 
deoxyhexose ([M+2H]2+ = 1451.17 m/z), while less than 2 % was modified with a 
deoxyhexose and ~7% was unmodified. The 1451.17 m/z peak was isolated and the CID 
normalized collision energy (CE) was incrementally increased (Fig 1). At the CEs required 
for fragmentation of the peptide backbone, the peptide underwent neutral losses producing a 
dominant doubly charged ion matching the mass of the unmodified peptide ([M+2H]2+ = 
1297.11 m/z) as well as lower-intensity doubly charged species matching the mass of the 
peptide modified with a single deoxyhexose (i.e., fucose, [M+2H]2+ = 1370.14 m/z). MS2, 
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MS3 and MS4 of these species confirmed the sequential loss of Glc and Fuc as well as the 
sequence of the peptide (Fig S1). Taken together, these spectra demonstrate that the peptide 
was modified with an O-linked hexosyldeoxyhexose, i.e. O-Fuc-Glc. Upon fragmentation at 
a CE typical of peptide sequencing (i.e. 35%), the precursor and fragment b- and y-ions 
were predominantly stripped of the labile glycan, resulting in an MS2 spectrum effectively 
identifying the unmodified peptide. However, two fragment ions retaining the glycan were 
detectable, enabling positive localization of the O-Fuc-Glc to the Thr residue of the 
conserved O-fucosylation motif.
Recombinant PfTRAP was digested with trypsin and analyzed by nanoLC-MS/MS 
employing a data-dependent analysis (DDA) approach. An inclusion list was used to target 
the parent ion of the glycosite-bearing peptide modified with a mass equal to two hexoses 
and a deoxyhexose ([M+2H]2+ = 1329.03 m/z). The precursor ion was fragmented at 
incrementally increasing CEs as above (Fig S2). As with the recombinant PfCSP, CID 
resulted in neutral loss of the O-linked glycan, revealing that the peptide was modified with 
an O-linked hexosyldeoxyhexose, i.e. O-Fuc-Glc, as well as a hexose at a single Trp residue, 
i.e. C-Man (Fig 2). Unlike O-linked glycans, C-Man withstands CID and is readily localized 
from the dominant b- and y-ions. Furthermore, C-Man can undergo cross-ring cleavage 
resulting in a neutral loss of 120.04 Da (C4H8O4) and producing diagnostic precursor and 
fragment ion peaks 3. Notably, two isobaric 1329.03 m/z species were present that had 
distinct LC retention times (Fig 2A), and had the C-Man attached at the first or the second 
Trp residue of the WXXW motif (Fig 2B and C).
Identification of O-fucosylated proteins by automated sequence database searching
Automated MS/MS sequence database search tools routinely identify protein PTMs by 
allowing for variable modification of peptide residues with fixed masses. However, standard 
automatic search approaches are unable to identify O-glycosylated peptides such as those 
described above because the most intense fragment ions lack the glycan and thus do not 
match the predicted fragmentation spectra. Nonetheless, based on the observation that the 
MS2 spectra of such peptides can confidently identify the sequence of the unmodified 
peptide, we reasoned that these peptides could be identified by a sequence database search 
engine if the neutral loss of the glycan could be accounted for. To this end, we modified the 
open-source MS/MS sequence database search tool Comet 17 by adding a new 
“mass_offsets” parameter that allows the user to specify neutral loss masses to be variably 
subtracted from precursor masses of fragment spectra. For example, in the case of the O-
glucosylfucosylated PfCSP peptide described above, the parent ion had a mass of 2900.32 
Da([M+2H]2+ = 1451.17 m/z). By directing Comet to variably subtract 308.11 Da (equal to 
neutral loss of O-Fuc-Glc) from the precursor mass, the new predicted precursor mass of the 
peptide would be 2592.21 Da ([M+2H]2+ = 1297.11 m/z), matching the mass of the peptide 
identified by the unmodified peptide fragment ions in the MS2 spectrum for this species. We 
re-engineered the TPP to accommodate PSMs identified using the new “mass_offset” 
parameter, and we further re-engineered the automated spectral annotation tool Lorikeet to 
automatically annotate neutral loss of 120 Da from cross-ring cleavage of C-man, a PTM 
often found in close proximity to O-Fuc on TSRs. The data analysis workflow is 
summarized in Fig 3.
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To demonstrate this modified search approach, the recombinant PfTRAP tryptic digest was 
again analyzed by a DDA method, this time employing an inclusion list that targeted the 
glycosite-containing peptide at multiple masses corresponding to modification with the 
various combinations of two, one, or no C-Man and an O-Fuc-Glc, O-Fuc, or no O-linked 
glycan. MS2 spectra were searched using Comet with allowed mass offsets of 0, 146.06, and 
308.11 Da (no offset, loss of O-Fuc, and loss of O-Fuc-Glc, respectively), as well as variable 
modification of +162.05 @ Trp for C-Man. The results of the Comet search were analyzed 
with the TPP and peptide spectra matched with a mass offset were identified by sorting 
according to the “massdiff” field in the TPP’s PepXML Viewer. This value was calculated 
for each PSM as the difference between the predicted mass of the identified peptide and the 
observed mass of the precursor ion (Table S2). The glycosite-containing peptide was 
detected with multiple combinations of glycans (Table 1). It was imperative to cross 
reference these results with the extracted ion chromatograms of the identified species, as loss 
of glycans due to in-source fragmentation gave rise to spurious identifications (Fig 4). For 
example, each of the two positional isoforms of the singly C-mannosylated peptide ([M
+2H]2+ = 1174.98 m/z) co-eluted with its higher-abundance, higher-mass counterpart ([M
+2H]2+ = 1329.03 m/z) which was identified with a single C-Man as well as a mass offset of 
308.11 Da (O-Fuc-Glc). This observation is consistent with the 1174.98 m/z species at that 
retention time arising from neutral loss of the labile O-linked glycan due to in-source CID 
prior to MS2. Once properly accounted for, this in-source CID actually provided an 
additional line of evidence for differentiating between C-linked and O-linked glycans that 
are isobaric and otherwise indistinguishable by MS. Oxidation of tryptophan (likely 
introduced artificially during sample preparation) produced additional isobaric peptide 
species. For example, the peptide with a single oxidized Trp and an O-Fuc-Glc had the same 
mass as the peptide modified with two C-Man modifications, but these species were easily 
distinguished by MS2 and retention times (Table S2, Fig S3). The one case of 
indistinguishable isobaric species was observed with the most abundant glycoform, i.e. the 
peptide modified with a glucosylfucose. This glycoform was identified from the dominant 
LC peak at 59.7 min, the intensity of which was more than seven-fold greater than any other 
species. The glycopeptide was identified from multiple high-quality spectra, as was the co-
eluting peptide that had lost the disaccharide due to in-source fragmentation. Interestingly, 
another co-eluting pair of peptides with identical respective masses was identified at 57.8 
min. The MS2 spectra for these isobars were indistinguishable from their more abundant, 
later-eluting counterparts (Fig S4). The source of this peak splitting is unclear, as no other 
combination of expected glycans or oxidation states would give rise to the observed 
combination of precursor mass, MS2 spectra, and co-eluting peak pairs. If the dual peaks 
arose due to a chromatographic artifact or even conformational isomer of the same peptide, 
similar peak pairs would not likely be detectable for the other glycoforms identified in the 
sample - the minor peak intensity was only 2% of the dominant peak intensity, so additional 
minor peaks arising from the other, less-abundant species would likely be below the 
detection limit. While the major glycoforms were identified from multiple high-quality 
PSMs, there was one incorrect identification from a sparse, low-intensity PSM that was 
nonetheless assigned a high score. This PSM identified the doubly- mannosylated peptide 
with neutral loss of O-Fuc, but manual inspection of the MS2 spectrum revealed that it was 
actually an isobaric glycoform, the singly mannosylated peptide with neutral loss of O-Fuc-
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Glc. This correct identity could be determined from the mass of the dominant neutral loss 
precursor peak as well as the fact that multiple other MS2 from the same m/z and retention 
time correctly identified the singly mannosylated glycoform (Fig S5). The above examples 
demonstrate that, as with any MS/MS sequence database search tool, the resulting list of 
PSMs generated using our approach should always be confirmed by manual inspection of 
the data, especially when considering isobaric glycoforms. However, even the many isobaric 
glycoforms considered above could be confidently distinguished given sufficiently high-
quality spectra and chromatography.
Because our database searching strategy is amenable to standard instrumental approaches 
(i.e. untargeted DDA employing CID or HCD) and does not require identification of low-
mass oxonium ions or alternative fragmentation techniques 33–34, existing mass 
spectrometry data sets can be re-searched for evidence of O-fucosylation, even if the MS2 
data were collected at low resolution (e.g. using an ion trap). To demonstrate this, we re-
analyzed mass spectra from previously published proteomic analyses of P. falciparum, P. 
vivax, and P. yoelii salivary gland sporozoites. Proteomic analyses of salivary gland 
sporozoites have recently shown that the TSR domains of CSP and TRAP are glycosylated 
in vivo in the human-infective Plasmodium species P. falciparum 21 and P. vivax 22. 
Subsequent to those studies, it was demonstrated that the O-linked deoxyhexose observed in 
P. falciparum sporozoites is, in fact, O- Fuc, and the identity of the O-fucosyltransferase was 
confirmed as POFUT2 10. It has also been confirmed that P. falciparum possesses a version 
of the Dpy19 C-mannosyltransferase capable of modifying the TSR domain of PfTRAP with 
C-Man35. Because of the confounding effect of labile O-linked glycans on MS/MS sequence 
database searching, the evidence for in vivo O-fucosylation of Plasmodium parasites in the 
studies mentioned above was obtained by manually interpreting tandem mass spectra of 
peptides matching the predicted mass of glycosylated peptides. Here, we have re-analyzed 
those datasets with our new automated database searching approach and validated those 
original findings with dozens of high-quality PSMs. Furthermore, this reanalysis provides 
the first reported evidence of TSR glycosylation in the rodent-infective malaria parasite P. 
yoelii.
All data sets were acquired on an LTQ-Orbitrap with high resolution MS1 and low resolution 
MS2. The P. falciparum data, which includes a global proteome analysis 20 and a 
biotinylated surface-enriched sample 21, were part of the original evidence presented for O-
fucosylation of TSRs in plasmodium 21, and the P. vivax dataset subsequently demonstrated 
TSR glycosylation in that species as well 22. In those analyses, select MS2 spectra from 
parent ions matching predicted masses were manually annotated to provide evidence of O-
fucosylation and C-mannosylation. Re-analyzing the mass spectral data with our automated 
database searching approach confirmed the original findings and provided extensive 
additional evidence for these modifications from the same data sets (Fig 5, Table 2, Table 
S3, Fig S6-S14). Re-analyzing the P. yoelii data resulted in the first reported evidence of 
glycosylation of TSRs in that species (Fig 4, Fig S12-14, Table S3). CSP and TRAP in P. 
yoelii were O-fucosylated at the peptides bearing the conserved glycosites in the TSR 
domain. Both CSP and TRAP were only detected with O-Fuc; no evidence was observed for 
the glycosite-bearing peptides from either protein in unmodified form or modified with a 
Fuc-Hex disaccharide (Fig S12, Fig S13). Both proteins were also C-mannosylated in the P. 
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yoelii sample. As in P. falciparum, 100% of the TRAP observed in the P. yoelii sample was 
C-mannosylated, and always at the second Trp residue of the WXXW motif, in marked 
contrast to the recombinant PfTRAP expressed in mammalian cells, which exhibited all four 
possible C-Man site occupancy combinations (Table 1), and P. vivax, in which C-Man was 
not observed at all on TRAP. The presence or absence and site localization of C-Man could 
be made unambiguously from intact C-Man on fragment ions. The majority of CSP was C-
mannosylated (~96% based on LC peak height), a modification not observed on CSP in P. 
falciparum or P. vivax. This observation confirms that, at least in P. yoelii, Plasmodium 
Dpy19 is capable of mannosylating the WXXC motif even in the absence of a preceding 
WXXW motif35.
For all of the Plasmodium salivary gland sporozoite datasets analyzed, the FDR calculated 
by PeptideProphet generally agreed with the decoy-estimated FDR; at a probability 
corresponding to a model-estimated FDR of 1% (which should equal a decoy-estimated 
FDR of approximately 0.5% after excluding the known decoys, assuming half of the 
incorrect answers are decoys), the decoy-estimated FDRs for the datasets ranged from 
0.26 % to 0.56 %. Among the PSMs identified above this cut-off with a putative neutral loss 
of 146.06 or 308.11, none were decoy proteins. However, other real protein entries were 
identified that were likely false positives (Table 2, Table S3). The most common of these, 
appearing in four of the five datasets, were semi-tryptic fragments of a 39-residue human 
keratin peptide found in the contaminant database. The N-terminus of the fully tryptic 
peptide began with the sequence GSY. The mass of Gly-Ser is 144.05 Da and the mass of 
Gly-Ser-Tyr is 307.11. Combined with a mass error of two or one protons, respectively, 
arising from the incorrect isotope peak being identified as the monoisotopic peak of the 
precursor peptide ion, these mass errors were within the matching tolerance of the allowed 
neutral losses of 146.06 and 308.11 Da corresponding to O-Fuc and O-Fuc-Glc, respectively 
(Fig S15). Considering only fully tryptic peptides eliminated these false positives and nearly 
all others (Table 2), and further considering only the highest quality PSM (those with 
PeptideProphet probabilities above 0.99 and Expect scores below 10-5) eliminated the 
remaining spurious fully tryptic peptides. The above observations underscore the importance 
of manual validation of results obtained from this database searching approach. In the case 
of the samples analyzed here, the vast majority of PSMs identified with putative neutral loss 
of an O-linked glycan were peptides containing the expected glycosylation sites, and manual 
inspection of the MS2 spectra confirmed the quality of the matches.
Taken together, these data demonstrate a marked variety in glycan site occupancy on 
conserved TSR domains within and across Plasmodium species, inviting the question of 
what roles these glycans play in TSR proteins and whether these roles are protein- and 
species-specific. Importantly, these data also begin to suggest a recognition motif for the 
Plasmodium C-mannosyltransferase. Further work will be required to confirm this motif and 
whether the recognition sequence is conserved across Plasmodium species. Also of interest 
is the variable detection of an additional hexose (presumably glucose) modifying O-Fuc. In 
the datasets analyzed here, the large majority of CSP and TRAP in salivary gland 
sporozoites of all species was O-fucosylated, but the disaccharide was only seen in P. 
falciparum and only on a small percentage of the CSP and TRAP present (Fig 5). Further 
work will be required to determine whether the failure to detect the disaccharide in the P. 
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vivax and P. yoelii datasets is due to instrumental detection limit or the true absence of the 
glycan. In other organisms this glycan extension is performed by β−1,3-glucosyltransferase 
(B3GLCT). Although there is a P. falciparum gene with some sequence homology to 
B3GLCT 20 (parasite-infected erythrocyte surface protein (PIESP1); PF3D7_0310400), this 
function has not been verified, and the biological importance of this modification for the 
parasite is unknown. Finally, it is important to note that the glycosite occupancy observed 
for Plasmodium proteins in vivo differed considerably from that observed for the 
recombinant proteins expressed in mammalian cells (compare Table 1 with Fig 5). The TSR 
domains of both PfCSP 36 and PfTRAP37 are part of subunit malaria vaccine candidates 38. 
Since glycosylation effectively changes antibody recognition epitopes 39, it is important to 
be able to match the glycosylation patterns of the recombinant protein subunit to those 
observed in vivo 15, 31–32, 40. The methods we have described here enable simple analysis of 
TSR glycosylation using standard proteomics techniques and open-source analysis software.
In conclusion, the open-source MS/MS sequence database search tool Comet was re-
engineered to enable automatic detection of gas-phase labile O-linked mono- and 
disaccharides. The analysis tools of the TPP were re-engineered to accommodate the new 
information obtained from this search strategy, enabling assignment of probabilities and 
FDRs to identified glycosylated peptides as well as visualization of the MS2 spectra, 
including neutral losses from cross-ring cleavage of C-Man. We used this search strategy to 
re-analyze published proteomics datasets, confirming manually annotated spectra that had 
identified O-fucosylated peptides in P. falciparum and P. vivax, as well as identifying 
previously unreported glycosylation in P. yoelii. While the workflow described here was 
developed in order to identify a very specific type of glycosylation (i.e. O-fucosylation of 
TSRs), the new “mass_offsets” parameter in Comet can be set by the user to search for any 
predicted neutral loss. Combined with the support of the TPP analysis suite, this workflow 
can in theory be used to detect peptides exhibiting neutral loss of any moiety that behaves in 
a similar fashion to O-Fuc, e.g. O-GlcNAc. These tools will enable researchers to identify 
these and other gas-phase labile PTMs using standard proteomics techniques, as well as to 
re-analyze existing datasets for evidence of glycosylation that were not previously searched 
for.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
FUNDING SOURCES
Research reported in this publication was supported by the National Institutes of Health National Institute of 
Allergy and Infectious Disease under award number K25AI119229 (KES), by the University of Washington’s 
Proteomics Resource under award number UWPR95794 (JKE), by the National Institutes of Health National 
Cancer Institute under award number R01CA031798 (TAS), by the National Institutes of Health National Institute 
of General Medical Sciences under award numbers R24GM127667 (EWD) and R01GM087221 (RLM), by the 
National Institutes of Health National Institute of Biomedical Imaging and Bioengineering under award number 
U54EB020406 (EWD), and by the National Science Foundation under award number 0923536 (RLM, KES). The 
content is solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health, University of Washington’s Proteomics Resource, or the National Science Foundation. 
Swearingen et al. Page 11
J Proteome Res. Author manuscript; available in PMC 2020 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript.
ABBREVIATIONS
TSR thrombospondin type 1 repeat
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Figure 1. Collision-induced dissociation of an O-fucosylated peptide.
A tryptic digest of recombinant P. falciparum circumsporozoite protein (CSP) was directly 
infused and analyzed by NSI-MS/MS. The precursor parent ion with [M+2H]2+ = 1451.17 
m/z, corresponding to the mass of the potentially glycosylated peptide plus a hexose and a 
deoxyhexose, was fragmented by collision-induced dissociation (CID) at multiple 
normalized collision energies (CE). (A) At CE = 22%, the precursor ion was mostly intact, 
but small doubly charged peaks (detail at right) were detectable at 1370.14 m/z and 1297.11 
m/z, corresponding to neutral loss of hexose (i.e. glucose) and hexose plus deoxyhexose (i.e. 
glucosylfucose), respectively. (B) Just a slight increase in collision energy to CE = 23 % was 
sufficient to fragment most of the parent precursor ion. The dominant species was the 
1297.11 m/z peak resulting from neutral loss of the O-linked disaccharide. Peptide fragment 
ions could be detected at very low levels (detail at right). Red triangles are O-Fuc, blue 
circles are Glc bound to O-Fuc by a β-1,3 linkage, neutral loss of water from fragment ions 
is indicated with “o”, and neutral loss of O-Fuc-Glc is indicated with “*”. Most fragment 
ions were missing the O-linked glycan. However, y13 and y14 peaks retaining the O-Fuc-Glc 
were detected, positively localizing the O-linked glycan to the expected Thr residue. The y13 
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and y14 fragments produced the highest abundance fragment ion peaks in CID spectrum of 
the unglycosylated peptide (Figure S1), a common feature of y-ions with N-terminal Pro 
residues. (C) At CE = 35 % the parent precursor was completely fragmented and the relative 
abundance of the peptide fragment ions had increased approximately four-fold, but the 
spectrum was still dominated by the intact peptide stripped of the glycan.
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Figure 2. Collision-induced dissociation of a C-mannosylated and O-fucosylated peptide.
A tryptic digest of recombinant P. falciparum thrombospondin-related anonymous protein 
(TRAP) was analyzed by LC-MS/MS. A targeted method was used that isolated the 1329.03 
m/z precursor ion matching the mass of the potentially glycosylated peptide plus two 
hexoses and a deoxyhexose. (A) Two isobaric glycoforms of the peptide, each a positional 
isomer of the singly C-mannosylated peptide, exhibited distinct LC retention times. (B&C) 
Representative MS2 spectra identifying the isoforms. Green circles are C-Man, green half-
circles are C-Man with neutral loss of 120.04 Da due to cross-ring cleavage, red triangles are 
O-Fuc, blue circles are Glc bound to O-Fuc by a β-1,3 linkage. Neutral loss of water from 
fragment ions is indicated with “o”, and neutral loss of O-Fuc-Glc is indicated with “*”. At 
the normalized collision energy employed (CE = 35 %), the parent precursor ion was 
completely fragmented, but the dominant peak matched that of the peptide after neutral loss 
of a hexose and a deoxyhexose, i.e. O-Fuc-Glc. No fragment ions retained the O-linked 
glycan, but the attachment site is known to be the C-terminal Thr residue in the conserved 
TSR motif. The remaining hexose withstood CID and could be localized to either one of the 
two Trp residues, consistent with C-Man. This identification and localization were further 
corroborated by neutral loss of 120.04 Da from cross-ring cleavage of C-Man.
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Figure 3. 
Summary of the data analysis workflow used to identify putatively O-fucosylated peptides 
via an automated sequence database search engine.
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Figure 4. Automated identification of multiple glycoforms of recombinant PfTRAP.
A tryptic digest of recombinant P. falciparum TRAP was analyzed by LC-MS/MS. A 
targeted method was used that preferentially selected masses corresponding to the 
potentially glycosylated peptide modified with the various combinations of two, one, or no 
C-Man modifications and an O-Fuc-Glc, O-Fuc, or no O-linked glycan. The glycoforms 
were identified using our automated database searching approach (See summary of results in 
Table 1). (A) Extracted ion chromatograms of the targeted m/z values (all are [M+2H]2+). 
Traces are offset for clarity. The peptide sequence is shown with the potential C-
mannosylation and O-fucosylation sites underlined. Peaks are labeled with the identified 
glycoform according to the inset legend. For the major species, evidence of neutral loss of 
the O-linked glycan due to in-source collision-induced dissociation prior to MS2 
fragmentation could be seen as lower-intensity, co-eluting peaks. (B) A representative MS2 
spectrum that has been automatically annotated by a version of the spectrum visualization 
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tool Lorikeet that was re-engineered to improve annotation of C-mannosylation and O-
fucosylation and is included with the Trans-Proteomics Pipeline, the free and open-source 
proteomics data analysis suite used to perform the analyses described here. The difference 
between the observed experimental precursor mass of 1329.0304 m/z and matched peptide 
mass of 1174.9770 m/z indicates that the PSM was obtained by the database searching 
program Comet allowing neutral loss of 308.11 Da (loss of O-Fuc-Glc) in the MS2. The 
dominant peak (yellow M++) at 1174.98 m/z is the peptide that has lost O-Fuc-Glc but 
retains C-Man. Neutral loss of 120.04 Da from cross-ring cleavage of C-Man is indicated as 
“−120” and neutral loss of water is indicated as “o”. The fragment spectra positively 
localized the C-mannose to the C-terminal Trp.
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Figure 5. In vivo glycosylation of Plasmodium TSR domains identified from re-analysis of 
published data.
Summarized here is the site occupancy of C-mannosylation and O-fucosylation of 
thrombospondin type 1 repeat (TSR) domains in circumsporozoite protein (CSP) and 
thrombospondin anonymous protein (TRAP) in Plasmodium salivary gland sporozoites as 
determined by automated database searching of previously published proteomics data. 
Detected glycans are indicated with triangles and circles as described in the legend. The 
hexose of the Fuc-Hex disaccharide is indicated as a generic hexose because neither the 
identity of the sugar nor its glycosyltransferase has been identified in Plasmodium. The 
approximate relative proportion of glycoforms in the analyzed samples is given as estimated 
by LC peak height (see Fig S6-13).Glycosylation of CSP and TRAP has been reported in 
salivary gland sporozoites of P. falciparum (Pf) 21 and P. vivax (Pv) 22. Our re-analysis of 
published data from P. yoelii (Py) salivary gland sporozoites 20 has provided the first 
evidence of TSR glycosylation in that species.
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Table 1.
Glycopeptides identified from LC-MS/MS analysis of recombinant PfTRAP.
A tryptic digest of recombinant P. falciparum TRAP expressed in mammalian cells was analyzed by LC-
MS/MS and the MS2 spectra were searched for evidence of O-linked fucose or glucosylfucose by our 
automated database searching method.
Modified Peptidea
O-linked
Glycanb
[M+2H]2+
m/zc
Retention
time (min)d
Proportion
in samplee PSMs
f
TASCGVWManDEWManSPCSVTCGK Fuc-Glc 1410.06 50.5 1.27% 9
TASCGVWDEWManSPCSVTCGK Fuc-Glc 1329.03 54.7 11.3% 19
TASCGVWManDEWSPCSVTCGK Fuc-Glc 1329.03 55.4 2.39% 11
TASCGVWDEWManSPCSVTCGK Fuc 1248.01 56.1 0.09% 3
TASCGVWManDEWSPCSVTCGK Fuc 1248.01 57.0 0.08% 1
TASCGVWDEWSPCSVTCGK Fuc-Glc 1248.01 57.8, 59.7 78.8% 120
TASCGVWDEWSPCSVTCGK Fuc 1166.98 61.4 4.91% 20
TASCGVWDEWSPCSVTCGK None 1093.95 61.6 1.18% 111
a
The peptide from the TSR domain of P. falciparum TRAP containing potential glycosylation sites. The localization of C-Man was directly 
detected from the MS2 fragment spectra. Any O-Fuc or O-Fuc-Glc is presumed to have been attached at the C-terminal Thr residue.
b
The identity of the O-linked glycan as inferred by the neutral loss of 146.06 Da (O-Fuc) or 308.11 Da (O-Fuc-Glc) from the parent mass upon 
MS2 fragmentation.
c
The m/z of the doubly charged peptide parent ion.
d
The retention time of the peptide (see Fig 4).
e
The relative proportion of the peptide in the sample based on chromatographic peak height (see Fig 4).
f
The number of high-quality peptide spectrum matches (PSMs) identifying the peptide (see Table S2). Note that the total number of PSMs 
identifying the unglycosylated peptide (1093.95 m/z) was artificially high due to neutral loss of the O-linked glycan from the highly abundant O-
fucosylated, unmannosylated species prior to MS2 fragmentation.
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Table 2.
Evidence for in vivo glycosylation of CSP and TRAP.
Previously published proteomics data from analyses of Plasmodium salivary gland sporozoites was re-
analyzed using our automated database searching approach for identification of neutral loss of O-linked fucose 
or glucosylfucose. Peptide spectrum matches (PSMs) in this table were identified with evidence for neutral 
loss of −146.06 (equal to deoxyhexose, i.e. fucose) or −308.11 (equal to hexosyldeoxyhexose, i.e. 
glucosylfucose).
Samplea
Total
PSMsb
CSP
PSMsc
TRAP
PSMsd
Decoy
PSMse
Non-Decoy
False
Positivesf
Fully Tryptic
Non-Decoy
False
Positivesg
P. vivax VK210 22 352 259 83 0 10 1
P. vivax VK247 22 250 171 33 0 46 0
P. falciparum
global proteome 20 57 54 0 0 3 1
P. falciparum
surface-enriched 21 12 0 4 0 8 1
P. yoelii 20 26 18 7 0 1 0
aSources of data are cited. VK210 and VK247 refer to different P. vivax haplotypes. No evidence for O-fucosylation of TRAP was observed in the 
P. falciparum global proteome dataset because the precursor ion, though highly abundant, was never selected for fragmentation because the 
instrument software was unable to assign a charge state to the isotope envelope, and the ion was accordingly excluded from monoisotopic precursor 
selection. A gel fraction containing TRAP from a surface-enriched P. falciparum sample was analyzed for spectral evidence of O-fucosylation of 
TRAP.
b
Total number of peptide spectrum matches (PSMs) identified with a neutral loss putatively corresponding to an O-linked glycan.
c
Total number of PSMs identifying the glycosite-containing peptide of CSP with evidence for O-fucosylation.
d
Total number of PSMs identifying the glycosites-containing peptide of TRAP with evidence for O-fucosylation.
e
The number of PSMs identified from decoy proteins.
f
The number PSMs identifying likely incorrect non-decoy proteins.
g
The number PSMs identifying fully tryptic peptides mapping to likely incorrect non-decoy proteins.
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